Paloma Partners’s BioNTech BNTX Stock Holding History

Paloma Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,509	Closed	-$322K	–	2071
2020 Q1	$322K	Buy	+5,509	New	+$214K	0.02%	653

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Paloma Partners's BNTX Position: Q2 2020 in Review

Paloma Partners sold out of BioNTech (BNTX) in Q2 2020, closing a stake of 5,509 shares — an estimated $322K sold.

Paloma Partners first reported a position in BNTX in Q1 2020 and held it in 1 quarter. The position peaked at $322K in Q1 2020. 109 funds tracked by Wall St. Rank hold BNTX as of Q2 2020.

Paloma Partners reported no remaining BioNTech position as of Q2 2020 after selling out during the quarter.
Paloma Partners sold 5,509 BioNTech shares in Q2 2020, an estimated $322K.
Paloma Partners first reported a position in BioNTech in Q1 2020 and held it in 1 quarter.
Paloma Partners's BioNTech position peaked at $322K in Q1 2020.
109 funds tracked by Wall St. Rank held BioNTech as of Q2 2020.

Based on Paloma Partners's 13F filing for Q2 2020, filed 14 Aug 2020.